Alcresta Therapeutics, Inc.

Alcresta Therapeutics develops enzyme-based products for rare disease patients requiring enteral nutrition. The company specializes in addressing fat malabsorption disorders, particularly exocrine pancreatic insufficiency, in pediatric and adult patients receiving tube feeding at home or in clinical settings. Alcresta's primary product, RELiZORB® cartridge containing iLipase® (immobilized lipase), is a patented microbead enzyme technology designed to mimic pancreatic lipase function and facilitate fat digestion and absorption in enterally fed patients. RELiZORB is indicated for patients with cystic fibrosis, short bowel syndrome, pancreatitis, digestive cancers, and other conditions causing fat malabsorption. The product is the first and only enzyme product formulated for use directly in enteral feeding systems. Alcresta has received FDA clearance, including recent expanded use authorization for neonates and infants (November 2025). The company conducts clinical research to support product efficacy, including Phase 3 exploratory studies and real-world evidence registries demonstrating growth improvements in pediatric patients. Manufacturing capabilities include enzyme immobilization technology and cartridge formulation. Alcresta serves hospital and home care markets, targeting gastroenterology, pediatrics, and rare disease specialties.